Live from TCT

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
 
Justine Cadet, News Editor
 
The news from this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C., revealed the truth in the words of Jonathan Swift to the interventional community: There is nothing constant in this world but inconsistency.

Dr. Martin B. Leon, chairman emeritus of the Cardiovascular Research Foundation (CRF), which sponsors TCT, reported that the utilization of DES has experienced a 1.3 percent increase for PCI this year in the Drug-Eluting Stent (DES) Summit. This may represent a “soft rebound” from the 10 percent drop that stenting endured in 2007. However, he also noted that the CABG experienced 22 percent increase for 2008. Based on these figures, physicians are slowly beginning to readopt PCI as a treatment option, but are still hesitant about widespread utilization.

The initial results of the Boston Scientific SYNTAX study, which were presented at the European Society of Cardiology (ESC), indicated that CABG was preferable to stenting in the sickest patient populations. However, new subgroup analysis from SYNTAX presented this week showed equivalent safety and efficacy endpoints between PCI and CABG amongst patients with unprotected left main disease, and showed improved efficacy outcomes in triple-vessel disease.

On a truly positive note for DES, the one-year HORIZONS AMI results found that the use of a DES in patients can significantly reduce rates of target lesion revascularization and binary angiographic restenosis when compared to bare metal stents. The impact of this trial is fueled by the large number of enrollees: 3,602 STEMI patients in 11 countries.

However, in a disturbing real-life analysis, JAMA researchers revealed Wednesday that Medicare recipients who undergo elective PCI often do not receive the recommended stress tests to confirm that angioplasty is warranted.

While the 10,000 attendees of TCT heard many studies and presentations employing the best practices in interventional cardiology, the communication of these methods remains integral for those treatment options to be employed in the practical setting.

Please look for continued TCT news in next week’s newsletter.

On these topics, or any others, please feel free to contact me.

Justine Cadet, News Editor
jcadet@cardiovascularbusiness.com

Justine Varieur Cadet

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.